{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:57:46Z","timestamp":1771484266057,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2015,7]]},"abstract":"\n Objectives<\/jats:title>\n \n To investigate the association between lymphovascular invasion (\n LVI<\/jats:styled-content>\n ) and clinical outcome in organ\u2010confined, node\u2010negative urothelial cancer of the bladder (\n UCB<\/jats:styled-content>\n ) in a\n post hoc<\/jats:italic>\n analysis of a prospective clinical trial. To explore the effect of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (\n MVAC<\/jats:styled-content>\n ) on outcome in the subset of patients whose tumours exhibited\n LVI<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n Surgical and tumour factors were extracted from the operative and pathology reports of 499 patients who had undergone radical cystectomy (\n RC<\/jats:styled-content>\n ) for\n pT<\/jats:styled-content>\n 1\u2013T2\u00a0\n N<\/jats:styled-content>\n 0\n UCB<\/jats:styled-content>\n in the p53\u2010\n MVAC<\/jats:styled-content>\n trial (\n S<\/jats:styled-content>\n outhwest\n O<\/jats:styled-content>\n ncology\n G<\/jats:styled-content>\n roup 4\n B<\/jats:styled-content>\n 951\/\n NCT<\/jats:styled-content>\n 00005047). The presence or absence of\n LVI<\/jats:styled-content>\n was determined by pathological examination of transurethral resection or\n RC<\/jats:styled-content>\n specimens. Variables were examined in univariate and multivariate\n C<\/jats:styled-content>\n ox proportional hazards models for associations with time to recurrence (\n TTR<\/jats:styled-content>\n ) and overall survival (\n OS<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 499 patients with a median follow\u2010up of 4.9\u00a0years, a subset of 102 (20%) had\n LVI<\/jats:styled-content>\n \u2010positive tumours. Of these, 34 patients had\n pT<\/jats:styled-content>\n 1 and 68 had\n pT<\/jats:styled-content>\n 2 disease.\n LVI<\/jats:styled-content>\n was significantly associated with\n TTR<\/jats:styled-content>\n with a hazard ratio (\n HR<\/jats:styled-content>\n ) of 1.78 [95% confidence interval (\n CI<\/jats:styled-content>\n ) 1.15\u20132.77; number of events (\n EV<\/jats:styled-content>\n ) 95;\n P<\/jats:italic>\n = 0.01) and with\n OS<\/jats:styled-content>\n with a\n HR<\/jats:styled-content>\n of 2.02 (95%\n CI<\/jats:styled-content>\n 1.31\u20133.11;\n EV<\/jats:styled-content>\n 98;\n P<\/jats:italic>\n = 0.001) after adjustment for pathological stage. Among 27 patients with\n LVI<\/jats:styled-content>\n \u2010positive tumours who were randomised to receive adjuvant chemotherapy, receiving\n MVAC<\/jats:styled-content>\n was not significantly associated with\n TTR<\/jats:styled-content>\n (\n HR<\/jats:styled-content>\n 0.70, 95%\n CI<\/jats:styled-content>\n 0.16\u20133.17;\n EV<\/jats:styled-content>\n 7;\n P<\/jats:italic>\n = 0.65) or with\n OS<\/jats:styled-content>\n (\n HR<\/jats:styled-content>\n 0.45, 95%\n CI<\/jats:styled-content>\n 0.11\u20131.83;\n EV<\/jats:styled-content>\n 9;\n P<\/jats:italic>\n = 0.26).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Our\n post hoc<\/jats:italic>\n analysis of the p53\u2010\n MVAC<\/jats:styled-content>\n trial revealed an association between\n LVI<\/jats:styled-content>\n and shorter\n TTR<\/jats:styled-content>\n and\n OS<\/jats:styled-content>\n in patients with\n pT<\/jats:styled-content>\n 1\u2013\n T<\/jats:styled-content>\n 2\n N<\/jats:styled-content>\n 0 disease. The analysis did not show a statistically significant benefit of adjuvant\n MVAC<\/jats:styled-content>\n chemotherapy in patients with\n LVI<\/jats:styled-content>\n , although a possible benefit was not excluded.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12997","type":"journal-article","created":{"date-parts":[[2014,11,21]],"date-time":"2014-11-21T05:34:45Z","timestamp":1416548085000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Significance of lymphovascular invasion in organ\u2010confined, node\u2010negative urothelial cancer of the bladder: data from the prospective p53\u2010\n MVAC<\/scp>\n trial"],"prefix":"10.1111","volume":"116","author":[{"given":"Friedrich\u2010Carl","family":"von Rundstedt","sequence":"first","affiliation":[{"name":"Scott Department of Urology Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A.","family":"Mata","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Groshen","sequence":"additional","affiliation":[{"name":"USC Norris Comprehensive Cancer Center University of Southern California Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Stein","sequence":"additional","affiliation":[{"name":"Aresty Department of Urology Keck School of Medicine University of Southern California Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Skinner","sequence":"additional","affiliation":[{"name":"Aresty Department of Urology Keck School of Medicine University of Southern California Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology Department of Medicine University of Chicago Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Cote","sequence":"additional","affiliation":[{"name":"Department of Pathology Miller School of Medicine University of Miami Miami FL USA"},{"name":"Department of Biochemistry and Molecular Biology Miller School of Medicine University of Miami Miami FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr N.","family":"Kryvenko","sequence":"additional","affiliation":[{"name":"Department of Pathology Miller School of Medicine University of Miami Miami FL USA"},{"name":"Department of Urology Miller School of Medicine University of Miami Miami FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Godoy","sequence":"additional","affiliation":[{"name":"Scott Department of Urology Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[{"name":"Scott Department of Urology Baylor College of Medicine Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.03.023"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089259"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.4028"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09217.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hye086"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000043639.55877.17"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.07.056"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.516"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11455.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2012.10.002"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.040"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.07.061"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1590"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12997","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:56:52Z","timestamp":1761749812000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,25]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/bju.12997"],"URL":"https:\/\/doi.org\/10.1111\/bju.12997","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,25]]},"assertion":[{"value":"2015-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}